Sacroiliitis Treatment Market Report 2026

Sacroiliitis Treatment Market Overview

• Sacroiliitis Treatment market size has reached to $1.77 billion in 2025 • Expected to grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Surge In Joint Disorders Fueling The Growth Of The Market Due To Rising Aging Population And Musculoskeletal Stress • Market Trend: FDA Clearance Accelerates Launch Of Innovative Minimally Invasive Sacroiliitis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sacroiliitis Treatment Market?

Sacroiliitis treatment refers to the medical care used to manage inflammation of one or both sacroiliac joints, located where the lower spine meets the pelvis. This condition can cause pain in the lower back, buttocks, or legs and may be associated with inflammatory conditions like ankylosing spondylitis. The primary goal of treating sacroiliitis is to reduce inflammation, relieve pain, and restore mobility. The main types of sacroiliitis treatment are medications, joint injections, joint fusion, radiofrequency denervation, and electrical stimulation. Medications for sacroiliitis primarily include nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics that help reduce pain and inflammation in the sacroiliac joint. It includes various diagnoses, including imaging tests, physical examinations, laboratory tests, and others administered orally, injectably, or topically. It serves a wide range of end users, including hospitals, specialty clinics, ambulatory surgical centers, and home care settings.

What Is The Sacroiliitis Treatment Market Growth Forecast?

The sacroiliitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing adoption of biologic drugs, rising demand for minimally invasive pain treatments, expansion of outpatient orthopedic procedures, growing integration of digital diagnostics, increasing focus on long-term mobility restoration. Major trends in the forecast period include increasing use of image-guided diagnostic techniques, rising adoption of minimally invasive si joint fusion, growing preference for biologic and targeted therapies, expansion of radiofrequency-based pain management, enhanced focus on personalized treatment approaches.

What Is The Driver Of The Sacroiliitis Treatment Market?

The increasing incidences of joint disorders are expected to propel the growth of the sacroiliitis treatment market going forward. Joint disorders are conditions that affect the joints, causing pain, inflammation, stiffness, and impaired movement due to factors like injury, aging, autoimmune diseases, or infections. The incidence of joint disorders is increasing primarily because aging populations experience natural wear and tear on their joints, leading to a higher prevalence of conditions like osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment is helpful for joint disorders because it helps reduce inflammation and pain in the sacroiliac joints, improving mobility and overall joint function, which can alleviate symptoms and prevent further joint damage. For instance, in February 2024, according to the Arthritis Australia, an Australia-based non-profit organization, in 2025, osteoarthritis (OA) is projected to affect 2.35 million Australians (Figure 2), accounting for 57% of the total arthritis population and making it the most common form of arthritis in the country. By 2040, the number of Australians with OA is expected to rise to 3.11 million, representing a 32% increase from 2025. This corresponds to an additional 762,515 people living with OA in Australia by 2040 compared to 2025. Therefore, the increasing incidences of joint disorders are driving the growth of the sacroiliitis treatment industry.

Key Players In The Global Sacroiliitis Treatment Market

Major companies operating in the sacroiliitis treatment market are Pfizer Inc, Johnson And Johnson, AbbVie Inc, Novartis AG, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Amgen Inc, Biogen Inc, Sandoz Group AG, UCB SA, Hikma Pharmaceuticals PLC, Samsung Bioepis Co Ltd, Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co Ltd, Torrent Pharmaceuticals Limited, Globus Medical, Orthofix Medical Inc, Coherus BioSciences Inc, SI BONE Inc, Medtronic plc

Global Sacroiliitis Treatment Market Trends and Insights

Major companies operating in the sacroiliitis treatment market focus on obtaining regulatory approvals to accelerate the launch of innovative therapies, ensure market access, and strengthen their competitive positioning. Regulatory approvals refer to government health agencies' official authorization to confirm that medical treatment is safe and effective for public use. For instance, in December 2023, Spinal Simplicity, a US-based medical equipment manufacturer, received FDA 510(k) clearance for its Liberty-SI Lateral Implant System, a minimally invasive, transfixing device designed for sacroiliac joint fusion in patients with conditions such as sacroiliac disruptions and degenerative sacroiliitis. The system utilizes a lateral approach, inserting one or two titanium implants through the ilium and across the SI joint into the sacrum to provide stabilization and fusion. The implants feature a central threaded body with deployable wings and compressive elements, are available in multiple sizes, and are coated with hydroxyapatite to enhance integration. The procedure is intended to be safer and less invasive, potentially reducing anesthesia time and improving patient outcomes.

What Are Latest Mergers And Acquisitions In The Sacroiliitis Treatment Market?

In November 2023, Nevro Corp., a US-based medical device company specializing in innovative pain management solutions, acquired Vyrsa Technologies for an undisclosed amount. Through this acquisition, Nevro Corp. aims to strengthen its portfolio in minimally invasive treatments and accelerate the development and adoption of Vyrsa’s advanced spinal technologies by leveraging its commercial infrastructure and clinical expertise. Vyrsa Technologies is a US-based medical device company that offers a minimally invasive treatment option for sacroiliitis, explicitly focusing on sacroiliac joint fusion.

What Defines the Sacroiliitis Treatment Market?

The sacroiliitis treatment market includes revenues earned by entities by providing services, such as anti-inflammatory medications, pharmacological treatment, physical therapy, interventional pain management, surgical services, and chiropractic and osteopathic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sacroiliitis Treatment Market Report 2026?

The sacroiliitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sacroiliitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.